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ABSTRACT This article reviews a selection of presentations in the area of clinical problems that were
presented at the 2014 European Respiratory Society International Congress in Munich, Germany. We
review the most recent and relevant topics of interest in the area of clinical respiratory medicine,
encompassing novel reports and studies that are of particular interest to healthcare professionals. Topics
ranging from basic science to translation research are presented and discussed in the context of the most
up-to-date literature. In particular, the reviewed topics deal with chronic obstructive pulmonary disease
and asthma, idiopathic pulmonary fibrosis (pathogenesis and therapy), advances in functional chest
imaging, interventional pulmonology, pulmonary rehabilitation, and chronic care.
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MESSAGES FROM MUNICH
CLINICAL HIGHLIGHTS
Introduction
The 2014 European Respiratory Society (ERS) International Congress was held in Munich, Germany (fig. 1).
This meeting is the largest in the world in the area of respiratory medicine, exceeding 22000 attendees. In
2014, a total of 4390 abstracts were presented (80% acceptance rate), of which, around 20% dealt with
specific clinical problems and were referred to the ERS Clinical Assembly.
Methods
Abstracts were selected from presentations at the ERS 2014 International Congress that were available on
line. The selection was based on the individual group chairs’ preferences and evaluation of the perceived
importance of each relevant topic.
Clinical problems
Several new studies were presented at the Congress regarding pathogenesis, phenotyping and clinical/
therapeutic applications in chronic respiratory patients. Here, we report intriguing insights in the area of
chronic obstructive pulmonary disease (COPD) and other chronic conditions.
Chronic obstructive pulmonary disease
POLVERINO et al. [1] studied the role of B-cell activating factor (BAFF) in COPD. They quantified BAFF
expression in B- and T-cells in bronchoalveolar lavage (BAL) and blood samples of 38 COPD patients, 17
smokers and 20 nonsmokers by using flow cytometry. They found that BAFF expression was increased in
B- but not in T-cells in BAL and, to a lesser extent, in blood samples from COPD patients. Furthermore,
BAFF levels in BAL B-cells were inversely correlated with the severity of airflow limitation, suggesting that
B-cell expansion, mediated by BAFF, may be a critical event in the pathogenesis of the disease. The
problem of endothelial dysfunction was tackled by VUKIC DUGAC et al. [2] in two phenotypically distinct
groups of frequent and infrequent COPD exacerbators. Von Willebrand factor, as a marker of endothelial
dysfunction, and C-reactive protein and fibrinogen, as markers of systemic inflammation, were measured
in 117 consecutive subjects; a significantly higher increase of all markers in frequent than infrequent
exacerbators was found. The presence of allergic sensitisation (serum specific IgE for inhaled antigens) is
associated with worse baseline characteristics and clinical course in humans with COPD. SUZUKI et al. [3]
designed a 5-year prospective observational cohort study including 268 COPD patients. 67 (25%) subjects
had allergic sensitisation; this phenotype was not associated either with worse baseline characteristics
(post-bronchodilator forced expiratory volume in 1 s (FEV1), computed tomography (CT) emphysema
score and quality of life) or with clinical course (annual decline in FEV1 and exacerbation frequency).
The inflammatory pattern in the stable state and during exacerbation of COPD patients was reported by
SINGH et al. [4], who specifically investigated the levels of tumour necrosis factor (TNF)-α released level by
monocyte-derived macrophages (MDMs) stimulated by bacterial load. MDMs were cultured in inert beads
or with a heat-killed Haemophilus influenzae or Streptococcus pneumoniae and the TNF-α release level was
measured by ELISA. They found that H. influenzae is more pro-inflammatory than S. pneumoniae in both
clinical conditions. However, a significant increase in TNF-α release level from the stable to exacerbation
state was seen in response to S. pneumoniae only. These data guarantee future research about this response
and the relationship with phagocytosis.
FIGURE 1 A thematic poster session at
the 2014 European Respiratory Society
International Congress in Munich,
Germany. Image courtesy of Michael
Buxbaum, The International Center for
Documentary Arts, Chicago, IL, USA.
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BHATT et al. [5] faced the topic of the paradoxical response to bronchodilators in COPD, as defined by at
least 12% or 200 mL reduction in FEV1 and/or forced vital capacity (FVC) post-bronchodilator. They
included 9986 subjects from a large multicentre study (COPD-GENE); the paradoxical response was seen
in 4.54% of patients, was similar in those with COPD and in smokers without airflow obstruction, and was
independently associated with worse dyspnoea, higher BODE index and a greater frequency of
exacerbations. These subjects were younger, current smokers and African-Americans. The paradoxical
response to bronchodilators may therefore represent a novel COPD phenotype.
The problem of dealing with self-management in the population of exacerbated COPD patients was tackled
by ZWERINK et al. [6]. Over 2 years of follow-up, the self-treatment of exacerbations did not lead to a
decrease in the number or severity of exacerbations; however, it was shown to lead to fewer pulmonary
physician consultations, with no increase in hospitalisations or emergency department visits. An interesting
study from UK. [7] demonstrated that lower limb muscle mass measured by ultrasound predicts the risk of
rehospitalisation following admission for acute exacerbations of chronic respiratory disease.
Other lung diseases
Fibrosing mediastinitis is a rare but potentially fatal disease. WESTERLY et al. [8] evaluated the role of
rituximab in a small cohort of patients receiving a 2-month tapered dose of prednisone. Circulating B-cells
were depleted in all patients and all had favourable therapeutic responses (fig. 2).
LICHTBLAU et al. [10] preliminarily studied the feasibility and long-term effects of switching pulmonary
arterial hypertension (PAH) patients showing intolerable side-effects due to sildenafil to tadalafil. In six out
of 13 subjects, switching to tadalafil was feasible and resulted in better tolerated side-effects and a more
stable clinical course, achieving improvements in symptoms, 6-min walking distance, stable
echocardiographic findings, lung function and N-terminal pro-brain natriuretic peptide levels during a
follow-up of 11±3 months. In five out of 13 patients, adverse events occurred under tadalafil as well, so
therapy with phosphodiesterase (PDE)-5 inhibitors was discontinued. In two patients, sildenafil treatment
was successfully restarted after an intermittent switch to tadalafil. The observations of this study indicate that
a transition of PDE-5 inhibitors due to intolerable side-effects is reasonable in approximately half of patients.
LICHTBLAU et al. [11] investigated the role of stress Doppler echocardiography (SDE) for early detection of
PAH in systemic sclerosis (SSc). They assessed 76 consecutive patients by echocardiography at rest, SDE,
and right heart catheterisation at rest and during exercise. The sensitivity of the diagnosis of PAH
increased up to 90% by using SDE, which may be a useful screening tool in patients with SSc. The clinical
efficacy of inhaled N-acetylcysteine in a heterogeneous group of patients with interstitial pneumonia
(idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia and connective tissue diseases
Pre-therapya)
Fibrosis
M
IP
FD
G 
PE
T/
CT
FD
G 
PE
T
M
IP
FD
G 
PE
T/
CT
FD
G 
PE
T
Post-therapy Post-therapy Post-therapyb) Post-therapy
SUVmax 7.1
MTV 172 cm3
TLG 630
VOI VOI VOI
VOI VOI VOI
VOI
VOI
VOI
VOI
SUVmax 5.1
MTV 70 cm3
TLG 219
SUVmax 4.8
MTV 63 cm3
TLG 186
SUVmax 4.9
MTV 77 cm3
TLG 231
SUVmax 4.6
MTV 29 cm3
TLG 84
Fibrosis
MyocardiumFibrosis
FIGURE 2 Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for
patient 2 at baseline (pre-therapy) and at 6 and 12 months of B-cell depletion (post-therapy). b) FDG PET/CT for patient 3 at baseline (pre-therapy) and
7 months after B-cell depletion (post-therapy). MIP: maximum intensity projection; VOI: volume of interest; SUVmax: maximum standardised uptake value;
MTV: metabolic tumour volume; TLG: total lesion glycolysis. Reproduced from [9] with permission from the publisher.
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(CTD)) was studied by OKUDA et al. [12]. Interestingly enough, they were able to show a lower rate of
reduction of FVC in subject treated over 6 months (−19 mL) when compared with a similar follow-back
period (−127 mL).
Rehabilitation and chronic care
Important advances in the area of rehabilitation and chronic care emerged demonstrating significant
benefits on essential outcomes such as functional capacity, symptoms, health-related quality of life and
healthcare utilisation. Accordingly, evidence was provided supporting the effectiveness and feasibility of
rehabilitation in patients with COPD, obstructive sleep apnoea, asthma, metastatic lung cancer or
malignant pleural mesothelioma, and interstitial lung disease (ILD), and in patients undergoing single- or
double-lung transplantation. Family- and community-based rehabilitation programmes were shown to be
effective in terms of improving functional capacity, assessed by the 6-min walk test, and quality of life. An
increasing number of studies performed in a conventional outpatient setting corroborated the positive
impact on daily physical activity assessed by triaxial accelerometers. The minimal clinically important
difference (MCID) in essential outcome measures of pulmonary rehabilitation, such as daily physical
activity, chronic dyspnoea and the incremental shuttle walk (ISW) test was also reported.
Along these lines, in a retrospective analysis, SCHNEEBERGER et al. [13] evaluated the effects of pulmonary
rehabilitation in 550 patients with COPD or ILD immediately after single- or double-lung transplantation.
While health-related quality of life improved to a similar extend in patients after both single- and
double-lung transplantation, exercise capacity improved significantly more in the latter population. In the
study by OLIVIER et al. [14], 71 patients treated for lung cancer or malignant pleural mesothelioma with
chemotherapy benefited from a rehabilitation programme combining electrostimulation or exercise training
with therapeutic education and psychosocial care, by exhibiting significant improvements in quality of life
and exercise capacity. In adults with moderate or severe asthma, aerobic training was shown to decrease
bronchial hyperresponsiveness and serum proinflammatory cytokines, while improving clinical control [15].
Interesting results were presented also on nonconventional pulmonary rehabilitation strategies. As pulmonary
rehabilitation often neglects the potential contribution of the family, MARQUES et al. [16] investigated the role
of family members participating in psychoeducation together with COPD patients. This family-based
programme was shown to enhance the coping resources of the family in managing COPD (fig. 3), and to be
feasible in that it did not interfere with conventional rehabilitation and its widely recognised patient benefits.
A community-based rehabilitation regimen incorporated in a self-management programme [17] showed a
sustained increase in daily physical activity despite a fall in maximal exercise capacity over 2 years.
Improvements in daily physical activity (monitored by total energy expenditure and active energy
expenditure by a triaxial accelerometer) were documented after a 10-week outpatient pulmonary
rehabilitation programme in patients with moderate to severe COPD regardless of the magnitude of
improvement in functional capacity assessed by the 6-min walk test [18]. The effectiveness of pulmonary
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FIGURE 3 A family-based pulmonary
rehabilitation (PR) programme
enhanced the coping resources of the
families of chronic obstructive
pulmonary disease patients. F-COPES:
Family Crisis Oriented Personal Scales.
Reproduced from [16] with permission
from the authors.
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rehabilitation in terms of improvement in daily movement intensity assessed by accelerometry was
reported following employment of a high-intensity interval exercise-training regimen [19].
While the study by DEMEYER et al. [20] corroborated the efficacy of pulmonary rehabilitation in improving
daily step counts in COPD, importantly, it also determined the magnitude of minimal important
difference (MID) of this outcome, which ranges between 576 and 1181 steps. The MID of the ISW test in
patients with COPD with a low baseline ISW distance was determined by NOLAN et al. [21] to be 40 m.
JOHNSON et al. [22] addressed the question of whether the MCID in chronic dyspnoea intensity should be
based on absolute or relative measures and concluded that it should be expressed as a relative reduction of
15–20% from baseline measurements.
Chest imaging
Even in the era of fused imaging studies, two presentations at the Congress showed that traditional
single-modality observer studies are still fundamental. In a retrospective analysis of 100 spirometer-controlled
CT scans at total lung capacity (TLC), VOS et al. [23] demonstrated that bronchopulmonary anatomical
variations are significantly frequent, i.e. nine anatomical variations were observed in 68% of patients. In
another observational study, HOYER et al. [24] showed that standard and basic chest radiograph is still
relevant in chest pain patients suspected of acute coronary syndrome; indeed, when combined with clinical
and laboratory information, it can rule out most differential diagnoses.
The role of lung imaging continues to move from purely morphological to a more functional approach,
which is nicely illustrated in sarcoidosis and COPD. Besides diagnostic achievements, technological
advances were also presented at the imaging sessions concerning these diseases. First, high-resolution CT
(HRCT) seems to be useful in the diagnosis of sarcoidosis, as many radiological patterns can be visualised
[25]. Interstitial thickening and nodular opacities are the most common parenchymal alterations while
paratracheal and symmetric hilar lymph node enlargement are the most common mediastinal abnormalities
on HRCT [26]. PAPIRIS et al. [27] examined, in 35 patients, the role of 18F-fluorodeoxyglucose positron
emission tomography/CT for the detection of thoracic and extrathoracic manifestations of sarcoidosis. They
detected few but clinically meaningful cases of cardiac, musculoskeletal and ocular sarcoidosis, leading to
more comprehensive therapeutic management. Cardiac sarcoidosis, occurring in up to 30% of patients with
pulmonary sarcoidosis, was investigated by STANTON et al. [28]. They identified that a mid-wall pattern of
late gadolinium enhancement is associated with a hyperintense myocardial signal on imaging, indicating
active inflammation, and with the presence of significant arrhythmias.
Reduced left ventricular cardiac performance is not only observed in the presence of severe emphysema
but also in hyperinflation due to abnormal lung function in COPD. Using lung function tests and Doppler
echography, PORAKHONKO et al. [29] found that COPD patients with hyperinflation (inspiratory capacity/
TLC ≤0.25) have impaired left ventricular diastolic filling. GALBAN et al. [30] used parametric response
mapping (PRM) of inspiratory/expiratory CT scans to monitor the longitudinal chances in COPD
subtypes. They found good correlations between the mathematical model simulations and PRM analysis of
CT in 76 patients, suggesting that functional small airway disease (i.e. COPD with nonemphysematous
tissue) may serve as a transitional phase from normal parenchyma to emphysema. This PRM model could
thus allow characterisation of COPD patients based on disease subtyping.
Pulmonary function testing provides only limited information on regional lung characteristics and, due to
issues of irradiation, the CT modality is not the first choice of repeated COPD monitoring examination.
Knowing that relaxation times in lungs depend on tissue composition including the blood volume fraction,
JOBST et al. [31] validated tissue and oxygen-enhanced (OE) mapping against first-pass perfusion magnetic
resonance imaging (MRI) in 20 COPD patients. Both of these correlated well with lung perfusion in the
different Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages. In particular, OE mapping
contributed to the differentiation of hypoxic vasoconstriction from genuine perfusion impairment.
Imaging with hyperpolarised helium-3 or xenon-129 (enriched 86%) gas ventilation MRI has been
proposed for direct visualisation of the local heterogeneity due to match/mismatch and delayed ventilation,
but these noble gas techniques are too expensive to achieve sufficient image quality in the routine practice.
PARRA-ROBLES et al. [32] presented an alternative and relatively inexpensive method using natural-abundance
polarised xenon-129 (enriched 26%) gas with a regulatory-approved polariser.
A few more innovative abstracts on functional imaging were presented and focussed at the level of alveolar
microstructures, where MRI and IPF came increasingly under the spotlight. Figure 4 illustrates a three-dimensional
picture model derived from helium-3 gas diffusion MRI projected on micro-CT images to generate models of acinar
airways, which allowed computer simulations illustrating the complexity of the lung microstructure [32].
HART et al. [33] applied the MRI phenomenon that the relaxation time in fibrotic lung is significantly
shorter than in healthy lung. Using the magnitude of this time shortening, the effect was significantly
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smaller in IPF patients than controls, indicating less efficient gas exchange in the pulmonary blood pool of
these patients.
In regards to the feasibility of noninvasive measurement of lung septal thickness with hyperpolarised
xenon-129 MRI in healthy volunteers and subjects with IPF, STEWART et al. [34] found that xenon-129 MRI is
sensitive detecting small changes in lung septa with the ageing of the lung that cannot be identified by usual
pulmonary function tests. Taken together, these new data encourage the use and further research of MRI not
only for functional assessment of COPD-associated diseases but also for other pulmonary parenchymal
diseases such as IPF, where MRI could also objectify the therapeutic advances towards IPF management.
Finally, the group of DE BACKER et al. [35] presented a combination of pulmonary function tests and
functional respiratory imaging. This research group found that disease progression in IPF is correlated
with reduced lobar volume and airway impedance and enlarged airway volume. Further studies need to
confirm these initial and innovative observations.
It is likely that the cooperation between different specialists and researchers (pathologists, pneumologists,
radiologists, physicist, engineers, statistician, etc.) will make imaging-based scientific progress possible in
the near future.
Interventional pulmonology
Endoscopic treatments for obstructive lung diseases
Promising data on novel procedures, as well as further insights on already established techniques, were the
major topics in the field of endoscopic treatments for obstructive lung diseases.
SLEBOS et al. [36, 37] presented the 1-year outcomes of a first-in-human feasibility study on targeted lung
denervation (TLD) in patients with moderate to severe COPD. Similar to anticholinergic drugs, TLD is
intended to reduce acetylcholine by the endoscopic ablation of parasympathetic nerves along the main
bronchi, using a catheter-based lung denervation system. TLD was performed in 22 moderate to severe
COPD patients, showing >15% FEV1 reversibility to ipratropium, at two different energy doses (20 or
15 W) in a staged fashion (two procedures with rigid bronchoscopy 30 days apart). Overall, sustained
improvements in bronchodilation, exercise endurance and quality of life were observed at 1-year follow-up
off bronchodilators, especially in the 20-Watt group [36]. However, data on safety were not completely
reassuring, as 16 dose-independent serious adverse events were reported. In particular, two severe adverse
events were reported, namely one sudden death and one gastric paresis [36, 37]. Encouraging data on
feasibility and long-term outcomes were reported also by VALIPOUR et al. [38], who performed TLD in both
lungs during a single procedure at 15 W in 15 COPD patients with the same eligibility criteria. TLD
showed a similar efficacy of long-acting muscarinic antagonists, as FEV1 and 6-min walking test off
tiotropium at 1-year follow-up were comparable to the baseline values on tiotropium. Notwithstanding,
a) b)
c) d)
FIGURE 4 a) Micro-computed
tomography data corresponding to a
helium-3 magnetic resonance imaging
voxel size of 7×7×7 mm and b) the
segmented single acinus volume. c) A
cross-section of segmented airspace
mask and d) a three-dimensional
helium-3 diffusivity distribution map
obtained from the computer
simulation. Reproduced from [32] with
permission from the authors.
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the benefit of such procedures in terms of cost-effectiveness profile, as well as the role of long-term
structural changes of the airway wall, need to be further investigated in large studies.
Due to the increasing diffusion of lung volume reduction treatments for advanced emphysema in daily
practice, a large amount of noteworthy experiences, mainly referring to coils and valve systems, was
presented at the Congress. New insights in lung volume reduction coil (LVRC) treatment included the
evidence of a significant improvement of chest wall asynchrony at optoelectronic plethysmography in a
well-designed, although small, controlled study [39] and the suggestion of favourable effects on ventilation/
perfusion relationship, assessed by iodine maps acquired by dual-energy CT [40]. The available data at
3-year follow-up showed an acceptable safety profile and an overall decline in benefits over time, although
there was still a significant number of responders. However, the high proportion of missing visits (42% of
patients did not attend the 3-year follow-up) could have introduced selection bias to outcome estimates [41].
The efficacy of endobronchial valve treatment was further confirmed in a high-quality experimental setting
[42], as well as in less “selected” subgroups of patients usually excluded from clinical trials, i.e. subjects
with FEV1 <20% of predicted or with established pulmonary hypertension (PH) [43, 44]. Even in these
patients, data on short-term safety still showed a relatively high occurrence of spontaneous pneumothorax,
although this seemed to be reduced by strict bed rest for the 2 days after the procedure [45].
Among the novel approaches for advanced emphysema treatment, encouraging results come from the
experience of biological lung volume reduction using a catheter-based autologous blood injection. These
preliminary data suggest an interesting cost-effectiveness profile [46]. The outcome at 1 year in 85 patients
with homogenous emphysema treated by bronchoscopic nitinol LVRCs was reported by MARCHETTI et al.
[47]. They showed that LVRCs, compared with patients treated by medical therapy alone, improved lung
mechanics (hyperinflation and air trapping) and exercise tolerance, thus suggesting a role for this
procedure in the most advanced homogeneous emphysema.
Diagnostic procedures
GUPTA et al. [48] addressed the issue of accuracy and safety of endobronchial ultrasound (EBUS)–
transbronchial needle aspiration (TBNA) over conventional TBNA in patients suspected of having
sarcoidosis; even though, individually, EBUS-TBNA has the highest diagnostic yield, it should be
combined with transbronchial lung biopsy to achieve optimal results. Notwithstanding, complementary
approaches [49], including rapid cytological analysis [50], have been raised in recent reports.
Interesting and new data on complementary techniques for transbronchial aspiration procedures were
presented at ERS Congress in 2014. ROZMAN et al. [51] investigated the role of ultrasound elastography
(EG) combined with EBUS-TBNA in the diagnostic work-up of mediastinal lymph nodes. EG allows
assessment of biomechanical properties of tissue by a strain ratio measurement, allowing differentiation
between benign and malignant lesions. At strain ratios ≥8, the accuracy of malignancy prediction in 66
mediastinal lymph nodes from 27 suspected lung cancer patients was 89.4%, showing it to be a reliable
tool for the selection of biopsy targets.
HERTH et al. [52] presented a first-in-human trial on the safety and yield of bronchoscopic transparenchymal
nodule access, a promising new image-guided technique for diagnostic flow in patients with small solitary
lung nodules. A straight-line path from an airway wall entry point to the target lesion was calculated using
software, and an access sheath and a 15-gauge stylet were advanced through parenchymal tissue under fused
CT/fluoroscopic guidance. Overall, the procedure was feasible, safe and accurate (yield 83%), and encourages
clinicians to plan further experiences in larger populations.
Interstitial lung diseases
At the 2014 ERS Congress, updates on the diagnosis, prognosis and/or treatment of both sarcoidosis and
IPF, the two most relevant ILDs, were presented. Additional interesting information came from studies of
systemic diseases associated with lung fibrosis.
Sarcoidosis
In patients with sarcoidosis, an easy staging system has recently been suggested to stratify patients and
identify those at high clinical risk by integrating the composite physiological index with HRCT
measurements [53].
When considering the natural course and prognosis of this lung disease, gene polymorphisms seem to
make an important contribution to the clinical phenotype. The presence of the TNFA 308A variant allele,
which relates to TNF-α production, has been associated with a better prognosis [54]. In addition, patients
without the TNFA 308A variant allele (GG genotype) had a three-fold higher responses to TNF inhibitors
(adalimumab or infliximab) [54].
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The therapy with adalimumab (40 mg weekly for 45 weeks), a fully human anti-TNF monoclonal
antibody, has been compared with infliximab in terms of both efficacy and safety in patients with
refractory pulmonary sarcoidosis [55]. Out of the 11 patients completing the study, seven stabilised their
lung volumes (FVC) and four improved. Moreover, adalimumab was associated with less use or
withdrawal of systemic steroids and immunomodulators in 27% of patients. Ustekinumab and golimumab
are monoclonal antibodies that specifically inhibit interleukin (IL)-12 and IL-23, and TNF-α, respectively.
Although well tolerated, neither treatment with ustekinumab nor golimumab showed efficacy in
pulmonary sarcoidosis [56].
Idiopathic pulmonary fibrosis
IPF is a chronic, progressive and rare ILD of unknown aetiology with a low survival rate. A global IPF registry
would facilitate a better understanding of disease molecular and cellular biology and behaviour, as well as
identification of regional variations in diagnostic and management patterns that will help establish better
treatment approaches [57]. The ASCEND trial [58] was designed to clarify the contrasting results of the earlier
studies (CAPACITY) with oral pirfenidone in IPF. In this trial, for the first time, pirfenidone significantly
improved progression-free survival and slowed the decline of FVC compared with placebo at 52 weeks.
The effect of pirfenidone on lung function and survival was then reported in those patients who were
previously randomised to the placebo group in the CAPACITY studies and then received this drug for the
first time [59]. Treatment was safe and generally well tolerated, with side-effects consistent with previous
reports; most importantly, the decline in FVC was significantly reduced in patients treated with
pirfenidone compared with placebo.
The INPULSIS trials are replicate phase III randomised studies comparing the efﬁcacy and safety of the
tyrosine kinase inhibitor nintedanib (150 mg twice per day) with placebo in patients with IPF [60].
Nintedanib reduces annual decline in lung function (FVC) by approximately 50%.
Other lung fibrosis
Safety and efficacy of treatment with bosentan, a dual endothelin-1 receptor antagonist, was reported in
patients suffering from confirmed PH associated with lung fibrosis (idiopathic interstitial pneumonia
(IIP)) [61]. This study showed no difference in invasive pulmonary haemodynamics, functional capacity or
symptoms between the bosentan and placebo groups over 16 weeks, thus suggesting the uselessness of
bosentan in these patients.
Identifying occult CTDs in patients with presumed idiopathic ILDs can be challenging and requires a
comprehensive, often multidisciplinary, evaluation. There is much uncertainty and controversy
surrounding the suggestive forms of CTD-associated ILD (CTD-ILD) and prospective studies are still
needed to provide a better understanding of the natural history of these cohorts. In the setting of CTDs,
some measures of ILD disease activity and severity may be confounded by nonpulmonary comorbidities.
A core set comprising specific measures in the domains of lung physiology, lung imaging, survival,
dyspnoea, cough and health-related quality of life was proposed to be appropriate for use in clinical trials
for either CTD-ILD or IPF [62].
A multicentre prospective study of 104 patients diagnosed as having IIPs or newly diagnosed CTD-ILD
treated with corticosteroids was conducted [63]. The pattern of usual interstitial pneumonia (by HRCT)
and a lower performance status have important prognostic implications in patients with IIPs.
General practice and primary care
At the 2014 Congress, some interesting data were presented dealing with the diagnosis and management
of respiratory diseases at the primary care level.
KOCKS et al. [64] identified different phenotypes in a broad spectrum of obstructive airway disease in a
primary care population. Data on 13 variables from a structured primary care asthma/COPD service were
used to identify clusters using hierarchical clustering. Six distinct groups were thus identified in this primary
care population. This might have relevant consequences in terms of both drug and long-care management.
The prevalence of COPD and related risk factors in a noncontinental rural area in Africa was investigated
[65]. The authors performed a population-based cross-sectional survey of 588 randomly selected subjects
above age of 30 years. Trained local healthcare workers used validated questionnaires and performed
spirometry. The prevalence of COPD was 16%, with the majority of both women and men exposed to
indoor biomass smoke. In the COPD group, 44% of the men were current and 24% former smokers, and
among women, 8% were current and 18% former smokers. They concluded that the prevalence of COPD
in Uganda is relevantly high in lower age groups, exposure to biomass smoke and smoking in men being
the two most significant risk factors.
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JONES et al. [66] had assessed the effect of the alternative methods of calculating the GOLD COPD categories
on their distribution and future risk of exacerbations (best assessed using the exacerbation frequency)
including the new cut-off values. They used data from more than 7000 primary care patients with valid data in
the UK. Depending on the method used, the proportion in category D varies from less than 5% to 46%. The
prospective relationship between the number of exacerbations and eosinophilia was studied by PRICE et al. [67]
in 13780 general practice patients with a diagnosis of COPD. The authors concluded that blood eosinophilia
occurs in stable COPD patients and is associated with a higher exacerbation risk, especially in nonsmokers
receiving maintenance treatment. The role of smoking in future exacerbation risk is still to be elucidated.
Regarding the change of individual’s characteristics over time, SUNDH et al. [68] examined factors
associated with change in DOSE index [69] in a 7-year follow-up study performed in COPD patients from
primary and secondary care, with data collected in between 2005 and 2012. The conclusion from this
study was that heart disease signals patients at risk of worsening their severity when assessed by DOSE.
KRUIS et al. [70] evaluated, in a 24-month cluster randomised controlled trial, the effects of integrated
disease management (IDM) in COPD patients compared to usual care. IDM consisted of integrated care
including spirometry, assessment of disease burden, exacerbation management, motivational interviewing,
physiotherapeutic reactivation and smoking cessation. They found improvement in the level of care
integration but failed to record any improvement in the primary outcome (difference in Clinical COPD
Questionnaire score at 12 months) compared to usual care.
Finally, in a study from Spain [71], authors evaluated a new model of integrated care in which hospital
specialists attend patients in different primary care centres. They assessed the impact of this model on the
management of respiratory diseases in a retrospective, observational study comparing two care models in
the same cohort of patients: conventional (prior model of care by pulmonologists not integrated into
primary care teams) and integrated. They found that the implementation of a respiratory care model
integrated into primary care improved the follow up of these patients by reducing the overall number of
visits for exacerbations, possibly due to the optimisation of the diagnosis and treatment.
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